February 20, 2005 -- The Centient Biotech 200 booked another small loss last week, falling a little more than 35 points to close at 3325.15, which represents a 1.05% slide. For the year thus far, the index has had five losing weeks against two gainers, and last week’s drop put it at a 7% loss for the year. Looking back over the past 52 weeks, the CBT 200 is 7% higher than its August lows, and 11.6% below the highs it hit during last year’s spring rally. We assess the fallout from the FDA Advisory Committee that considered the COX-2 inhibitors, plus we look at the companies where investors made the most money last week...
